Get the latest CIRM news, information on upcoming meetings, and funding opportunities delivered to your inbox.

The statewide network is designed to overcome manufacturing bottlenecks that have delayed or stalled development and approval of regenerative medicines. “These awards are a critical first step in ...

Title 17 California Code of Regulations Section 100080(f) designates all human pluripotent stem cell lines derived in accordance with the CIRM regulations as “acceptably derived.” These cell lines may ...

Get the latest CIRM news, information on upcoming meetings, and funding opportunities delivered to your inbox.

Members of the public who are listening to the meeting and wish to make a comment will have the opportunity to do so by doing the following: Once we have called for public comment, members of the ...

Jonathan Thomas, PhD, JD, is President and CEO of the California Institute for Regenerative Medicine (CIRM). Thomas was previously the Chair of the CIRM governing Board from June 2011 to March 2023.

Anne-Marrie Duliege, MD, is a Senior Executive and Chief Medical Officer with 30 years of experience guiding biopharmaceutical companies through development and commercial stages. Dr. Duliege is ...

Joseph Panetta is President & CEO and a member of the Board of Directors of Biocom California, the state association that advocates for 1800 companies, service sector firms, universities, and research ...

David Higgins, PhD, earned his PhD in molecular biology and genetics from the University of Rochester in New York, followed by a postdoctoral fellowship at the National Cancer Institute before moving ...

San Francisco, CA – California’s stem cell agency, the California Institute for Regenerative Medicine (CIRM) today approved $150 million in new funding to help move promising stem cell-based therapies ...

It takes a lot of effort to develop a promising stem cell research idea into an effective treatment that can help patients. CIRM funds a pipeline of projects spanning discovery, translation and ...